The drug company said it planned to issue capital expenditures of RS 700-800 Crore at the current fiscal at the addition of new high-speed charging and finish lines with lyophilizer on the Spokane (US) site and CRD expansion (research and development of service capacity contracts).
The Jubilant Pharmova drug firm on Friday reported Consolidated Net Profit Rs 214 Crore for the fourth quarter which ended on March 31, 2021. The company has posted a net profit of Rs 260 Crore in the January 2019-20 quarter.
Sales reached Rs 1,552 Crore for the fourth quarter while the same thing on Rs 1,497 Crore in the same period of FY20.
For all 2020-21 fiscal, the company reported the consolidated net income of Rs 836 Crore. It was Rs 898 Crore at FY20.
The latest sales of fiscal companies reached Rs 5,964 Crore, while the same was Rs 5,843 Crore at FY20.
The drug company notes that the numbers for the current quarter and year are not comparable to the previous period because of the business of life science (LSI) fall from it with the effect of February 1, 2021.
“… although Covid-19 challenges, income is stable because of a variety of businesses. CDMO and generic growing although we see the impact on radiofarma and have the impact of production at the Fire NanjiD factory,” said Chairman of the Pharmova Jubilant Shyam S Bhartia said in the regulation. Filing.
Apart from the locking related pandemic, the company has been able to ensure continuity in most of its manufacturing operations in all business segments while at the same time ensure employee security, he added.
The drug company said it planned to issue capital expenditures of RS 700-800 Crore at the current fiscal at the addition of new high-speed charging and finish lines with lyophilizer on the Spokane (US) site and CRD expansion (research and development of service capacity contracts). Jubilant Pharmova has a capex of Rs 276 Crore at FY21.
In generic business, the company records it plans to launch new products in the US through manufacturing in licenses and contracts.
“We hope to launch a new product from the ROPKEE website after a warning letter is appointed. We plan to increase geographical range in all world markets (rows),” he added.
The company’s board has recommended dividends Rs 5 per share Re 1 respectively, collects around RS 80 Crore, for the financial year ending March 31, 2021.
The company’s shares on Friday ended 0.82 percent at RS 836.2 each at BSE.